Phathom Pharmaceuticals (PHAT) to Release Quarterly Earnings on Thursday

Phathom Pharmaceuticals (NASDAQ:PHAT) is anticipated to issue its Q4 2025 results before the market opens on Thursday, February 26th. Analysts expect Phathom Pharmaceuticals to post earnings of ($0.09) per share for the quarter. Individuals can check the company’s upcoming Q4 2025 earning summary page for the latest details on the call scheduled for Thursday, February 26, 2026 at 8:00 AM ET.

Phathom Pharmaceuticals Trading Down 6.9%

NASDAQ:PHAT opened at $11.88 on Thursday. The company has a market capitalization of $848.47 million, a P/E ratio of -3.11 and a beta of 0.51. Phathom Pharmaceuticals has a 12 month low of $2.21 and a 12 month high of $18.31. The firm has a fifty day simple moving average of $14.77 and a 200-day simple moving average of $13.36.

Institutional Investors Weigh In On Phathom Pharmaceuticals

Hedge funds have recently modified their holdings of the company. Caitong International Asset Management Co. Ltd purchased a new position in shares of Phathom Pharmaceuticals in the 4th quarter valued at about $27,000. Raymond James Financial Inc. acquired a new stake in Phathom Pharmaceuticals in the second quarter valued at approximately $30,000. Kestra Advisory Services LLC purchased a new stake in shares of Phathom Pharmaceuticals in the fourth quarter valued at approximately $38,000. BNP Paribas Financial Markets increased its position in shares of Phathom Pharmaceuticals by 71.9% in the second quarter. BNP Paribas Financial Markets now owns 5,072 shares of the company’s stock valued at $49,000 after buying an additional 2,122 shares in the last quarter. Finally, Tower Research Capital LLC TRC raised its stake in shares of Phathom Pharmaceuticals by 58.3% during the 2nd quarter. Tower Research Capital LLC TRC now owns 5,710 shares of the company’s stock worth $55,000 after buying an additional 2,102 shares during the period. 99.01% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

PHAT has been the topic of several research analyst reports. Cantor Fitzgerald reiterated an “overweight” rating on shares of Phathom Pharmaceuticals in a research note on Wednesday, January 14th. Raymond James Financial started coverage on Phathom Pharmaceuticals in a research report on Thursday, December 11th. They issued a “strong-buy” rating and a $28.00 target price on the stock. Craig Hallum reissued a “buy” rating and set a $22.00 price target on shares of Phathom Pharmaceuticals in a research report on Friday, October 31st. HC Wainwright upped their price objective on shares of Phathom Pharmaceuticals from $20.00 to $26.00 and gave the company a “buy” rating in a report on Friday, October 31st. Finally, Guggenheim reissued a “buy” rating and set a $20.00 target price on shares of Phathom Pharmaceuticals in a report on Thursday, October 30th. One analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $20.71.

About Phathom Pharmaceuticals

Phathom Pharmaceuticals is a clinical‐stage biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases. The company’s core mission centers on addressing serious GI disorders by leveraging innovative mechanisms of action to improve patient outcomes. Phathom’s research and development efforts concentrate on conditions such as Helicobacter pylori infection, erosive esophagitis, gastroparesis and other functional GI disorders where significant unmet medical needs persist.

The company’s lead asset is vonoprazan, a potassium‐competitive acid blocker (P-CAB) licensed for use in the United States.